A prospective, multi-center, large-sample registry study of Angong Niuhuang Pill in the treatment of stroke

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100051118

Enrollment

Unknown

Registered

2021-09-14

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

Case series:Angong Niuhuang Pills

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The subject was clinically diagnosed with acute stage of stroke and the responsible lesion (infarct or hemorrhage foci) appeared on imaging, and the subject was prescribed Angong Niuhuang Pills for more than 3 days. 2. TCM diagnosis is phlegm-heat internal closure. 3. Subjects voluntarily enrolled in this study and signed a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with stroke caused by brain tumor, brain trauma, blood disease, rheumatic heart disease, coronary heart disease and other heart disease combined with atrial fibrillation; 2. Other patients deemed unsuitable by the investigator to participate in this study.

Design outcomes

Primary

Measure	Time frame
National Institutes of Health Stroke Scale Score;Modified Rankin Scale;	—

Countries

China

Contacts

Public ContactChen Lukui

Integrated Hospital of Traditional Chinese Medicine, Southern Medical University

18761886190@163.com+86 18761886190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026